WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015124932) 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/124932    International Application No.:    PCT/GB2015/050480
Publication Date: 27.08.2015 International Filing Date: 19.02.2015
IPC:
C07D 213/74 (2006.01), C07D 239/42 (2006.01), C07D 249/06 (2006.01), C07D 271/07 (2006.01), C07D 231/12 (2006.01), A61K 31/44 (2006.01), A61K 31/506 (2006.01), A61P 25/18 (2006.01)
Applicants: TAKEDA CAMBRIDGE LIMITED [GB/GB]; 418 Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0PA (GB) (MG only).
TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-Chome Chuo-Ku Osaka-Shi, Osaka 541-0045 (JP)
Inventors: FIELDHOUSE, Charlotte; (GB).
GLEN, Angela; (GB).
MAINE, Stephanie; (GB).
FUJIMOTO, Tatsuhiko; (JP).
ROBINSON, John Stephen; (GB)
Agent: JOHNSON, Stephen; (GB)
Priority Data:
14156011.0 20.02.2014 EP
Title (EN) 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
(FR) CYCLOPENTANES SUBSTITUÉS EN 1,2 UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR D'OREXINE
Abstract: front page image
(EN)The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
(FR)La présente invention concerne des composés de formule (I), ainsi que leurs sels pharmaceutiquement acceptables. Dans la formule (I), L,X, Ra, Rb, R1, R2 et R3 sont tels que définis dans la description. L'invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques contenant ces derniers et leur utilisation thérapeutique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)